Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Fortress Biotech (FBIO) Gains from Sales and Divestitures (2018 - 2025)

Fortress Biotech has reported Gains from Sales and Divestitures over the past 8 years, most recently at $365244.0 for Q4 2025.

Quarterly results put Gains from Sales and Divestitures at $365244.0 for Q4 2025, up 2010.87% from a year ago — trailing twelve months through Dec 2025 was $365244.0 (up 2010.87% YoY), and the annual figure for FY2025 was $365244.0, up 2010.87%.
Gains from Sales and Divestitures for Q4 2025 was $365244.0 at Fortress Biotech, down from $737132.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for FBIO hit a ceiling of $1.8 million in Q4 2022 and a floor of $607.0 in Q1 2024.
Median Gains from Sales and Divestitures over the past 5 years was $139858.0 (2022), compared with a mean of $297084.8.
Biggest five-year swings in Gains from Sales and Divestitures: tumbled 99.02% in 2024 and later soared 2010.87% in 2025.
Fortress Biotech's Gains from Sales and Divestitures stood at $712449.0 in 2021, then soared by 146.42% to $1.8 million in 2022, then crashed by 89.64% to $181831.0 in 2023, then plummeted by 90.48% to $17303.0 in 2024, then soared by 2010.87% to $365244.0 in 2025.
The last three reported values for Gains from Sales and Divestitures were $365244.0 (Q4 2025), $737132.0 (Q3 2025), and $11331.0 (Q2 2025) per Business Quant data.